Groundbreaking multi-site Yale study of psychosis engages biomarkers to reconfigure diagnoses

In a groundbreaking multi-site study, a comprehensive set of empirical biomarkers has been established to aid in diagnosis and treatment of psychosis – psychiatric syndromes characterized by delusions, hallucinations and disordered language.

To date, the “gold standard” for the diagnosis of psychosis has been clinical observation, classifying patients into schizophrenia, schizoaffective, and bipolar disorders. But in this study, the Bipolar Schizophrenia Network for Intermediate Phenotypes (B-SNIP) identified three neurobiologically distinct “Biotypes” that do not match up with the conventional clinical diagnosis.

“Instead of constructing psychiatric diagnoses traditionally in a top-down fashion using symptoms and clinical course, we have redefined them from the bottom-up using multiple, reliable, biologically-based measures,” said Dr. Godfrey Pearlson, Director of the Olin Neuropsychiatry Research Center at the Institute of Living in Hartford, and Professor of Psychiatry and Neurobiology at Yale University School of Medicine. “This strategy offers promising preliminary data that suggests a means to derive a biologic redefinition of psychotic syndromes that may help improve both the search for risk genes for these disorders, and to understand their biological origin in order to develop rationally-based new treatments.”

http://medicine.yale.edu/news/article.aspx?id=11696

4 Likes

**It`s about time! :pouting_cat: **